Drug Trial Radar · NCT03375502
A Study of MG1111 in Healthy Children
Last checked: Nov 19, 2026Latest source record: May 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
814
Actual
Start
Nov 26, 2016
Primary completion
Jan 29, 2019
Study completion Jul 31, 2019
Sponsor
- Lead sponsor
- Green Cross CorporationIndustry
- Sponsor type
- Industry
- First posted
- Dec 18, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 12 months, up to 12 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To assess the safety of MG1111 and to evaluate immunological non-inferiority of MG1111 versus comparator
Conditions
- Healthy Children
Interventions
Varicella VaccineDrug
The subject will receive investigational product or comparator.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects who achieved seroconversionTime frame: 42 days after vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The catholic university of Korea, Seoul st. mary's hospital
Banpo-dong, Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.